Cervical cancer screening in HIV-endemic countries: An urgent call for guideline change.
Cervical cancer
Global health
Guidelines
HIV
Prevention
Screening
Journal
Cancer treatment and research communications
ISSN: 2468-2942
Titre abrégé: Cancer Treat Res Commun
Pays: England
ID NLM: 101694651
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
08
2022
revised:
29
12
2022
accepted:
09
01
2023
pubmed:
23
1
2023
medline:
1
2
2023
entrez:
22
1
2023
Statut:
ppublish
Résumé
Women living with HIV (WLWH) are at an increased risk of developing HPV-related high grade cervical dysplasia and cervical cancer. Prior World Health Organization (WHO) screening guidelines recommended starting screening at age 30. We assessed characteristics of women diagnosed with cervical cancer to further inform and refine screening guidelines. We prospectively enrolled women diagnosed with cervical cancer from January 2015 to March 2020 at two tertiary hospitals in Gaborone, Botswana. We performed chi-square and ANOVA analyses to evaluate the association between age upon diagnosis and HIV status, CD4 count, viral load, and other sociodemographic and clinical factors. Data were available for 1130 women who were diagnosed with cervical cancer and 69.3% were WLWH. The median age overall was 47.9 (IQR 41.2-59.1), 44.6 IQR: 39.8 - 50.9) among WLWH, and 61.2 (IQR 48.6-69.3) among women living without HIV. There were 1.3% of women aged <30 years old, 19.1% were 30-39 and 37.2% were 40-49. Overall, 20.4% (n = 231) of cancers were in women <40 years. Age of cervical cancer diagnosis is younger in countries with higher HIV prevalence, like Botswana. Approximately 20% of the patients presented with cancer at <40 years of age and would have likely benefited from screening 10 years prior to cancer diagnosis to provide an opportunity for detection and treatment of pre-invasive disease.
Identifiants
pubmed: 36682141
pii: S2468-2942(23)00003-5
doi: 10.1016/j.ctarc.2023.100682
pmc: PMC9999385
mid: NIHMS1876285
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
100682Subventions
Organisme : NCI NIH HHS
ID : K08 CA230170
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA271949
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA190158
Pays : United States
Informations de copyright
Copyright © 2023. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Authors do not have any conflicts of interest to disclose.
Références
Lancet Glob Health. 2021 Feb;9(2):e161-e169
pubmed: 33212031
Afr J Reprod Health. 2003 Aug;7(2):7-12
pubmed: 14677294
Zhonghua Yi Xue Za Zhi. 2021 Sep 14;101(34):2653-2657
pubmed: 34404156
JCO Glob Oncol. 2022 Nov;8:e2200183
pubmed: 36395437
PLoS One. 2013 Sep 18;8(9):e74607
pubmed: 24058599
Int J Gynecol Cancer. 2011 Feb;21(2):363-6
pubmed: 21270617
BMJ Open. 2017 Aug 4;7(8):e015123
pubmed: 28780541
BMC Womens Health. 2022 Apr 2;22(1):100
pubmed: 35366863
BMC Public Health. 2012 Mar 23;12:237
pubmed: 22443255
AIDS. 2010 Oct 23;24(16):2553-61
pubmed: 20706107
Int J Cancer. 2014 Aug 15;135(4):896-904
pubmed: 24391021